Is Invitae Stock a Buy Now?

Invitae (NVTA 7.30%) has grown revenue over time, but the genetic testing specialist has failed to turn that into profit. Instead, the company burned through more and more cash, prompting it to launch a business realignment plan in 2022. The goal was (and is) to speed up the path to positive cash flow, and Invitae has made some progress.Despite efforts, Invitae shares have failed to take off and, instead, have lost more than 80% since the announcement of the new strategy. In fact, they've fallen to such a l ...